Lung Cancer
Conditions
Interventions
Treatment of afatinib Evaluation using MET-PET/CT
Sponsors
First Department of Internal Medicine, Shinshu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically or cytologically confirmed diagnosis of non-squamous cell and non-small cell lung cancer 2)Stage IV advanced unresectable, postoperative recurrent cancer 3)To detect following mutations by analysis of tissue or cell sample 4)Deletion in exon19 or L858R point mutation in exon 21 of EGFR gene 5)Brain metastasis verified by MRI or CT and >= 10 mm measurably 6)Using afatinib as first line treatment. 7)Age >= 20 years at obtained informed consent 8)ECOG performance status 0-2 9)The function of organs (marrow,liver,kidney,etc.)is maintained enough 10)Life expectancy >= 3 months
Exclusion criteria
Exclusion criteria: 1)Idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radiation pneumonitis, drug pneumonia, etc. are complicated 2)Active other malignancy 3)Adjuvant chemotherapy 4)Infection to need to treat with antibiotics or antifungal agent via intravenous administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate amino acid metabolic reactions obtained by followings To evaluate MET-PET/CT at baseline (SUVmax,L/N ratio) To evaluate MET-PET/CT at 4 and 8 weeks after start of therapy (SUVmax,L/N ratio) | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate relationship between amino acid metabolic reactions and following points PFS OS Response rate TTF Disease control rate | — |
Countries
Japan
Contacts
Public ContactKazunari Tateishi
Shinshu University First Department of Internal Medicine
Outcome results
None listed